ME01311B - N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora - Google Patents
N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptoraInfo
- Publication number
- ME01311B ME01311B MEP-2008-770A MEP77008A ME01311B ME 01311 B ME01311 B ME 01311B ME P77008 A MEP77008 A ME P77008A ME 01311 B ME01311 B ME 01311B
- Authority
- ME
- Montenegro
- Prior art keywords
- lower alkyl
- hydrogen
- phenyl
- halogen
- lower alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja opšte formule I je R vodonik, niži alkil, niži akoksi, halogen ili trifluormetil; R 1 je vodonik ili halogen; ili R i R 1 mogu biti zajedno sa ugljenikovim atomima prstena za koji su prikačeni - CH=CH-CH=CH-;R 2 i R 2 ' su nezavno jedan od drugog vodonik, halogen, trifluormetil, niži akoksi ili cijano; ili R 2 i R 2 mogu biti zajedno -CH=CH-CH=CH-, proizvoljno supstituisan sa jedn im ili dva supstituenta izabrana od nižeg alkil ili nižeg akoksi;R 3 , R 3 su nezavisno jedan od drugog vodonik, niži alkil ili cikloalkil; R 4 , R 4 su nezavisno jedan od drugog -(CH 2 ) m OR 6 ili niži alkil; ili R 4 i R 4 čine zajedno sa N-atomom za koji su prikačen i ciklični tercijarni amin grupe II R 5 je vodonik, hidroksi, niži alkil, -niži akoksi, -(CH 2 )OH, -COOR 3 , -CON(R 3 ) 2 , -N(R 3 )CO-niži alkil ili-C(O)R 3 ; R 6 je vodonik, niži alkil ili fenil;X je -(O)N(R 6 )- , -N(R 6 )C(O)-, -(CH 2 ) m O- ili -O(CH 2 ) m -; n je 0, 1, 2, 3 ili 4; i m je 1, 2 ili 3; i na njihove farmaceutski prihvatljive kisele adicione soli. Nađeno je da ova jedinjenja mogu da se koriste kao prolekovi za tretiranje ili prevenciju bolesti, povezanih sa NK1 receptorom .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00115287 | 2000-07-14 | ||
PCT/EP2001/007850 WO2002006236A1 (en) | 2000-07-14 | 2001-07-09 | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
ME01311B true ME01311B (me) | 2013-12-20 |
Family
ID=8169262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2008-770A ME01311B (me) | 2000-07-14 | 2001-07-09 | N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora |
Country Status (39)
Country | Link |
---|---|
US (4) | US6593472B2 (me) |
EP (1) | EP1303490B1 (me) |
JP (1) | JP3950044B2 (me) |
KR (1) | KR100501608B1 (me) |
CN (1) | CN1178917C (me) |
AR (1) | AR029717A1 (me) |
AT (1) | ATE400556T1 (me) |
AU (1) | AU7061901A (me) |
BR (1) | BRPI0112475B8 (me) |
CA (1) | CA2415890C (me) |
CY (1) | CY1108557T1 (me) |
CZ (1) | CZ303639B6 (me) |
DE (1) | DE60134749D1 (me) |
DK (1) | DK1303490T3 (me) |
EC (1) | ECSP034431A (me) |
EG (1) | EG24968A (me) |
ES (1) | ES2309075T3 (me) |
GT (1) | GT200100137A (me) |
HK (1) | HK1058198A1 (me) |
HR (1) | HRP20030003B1 (me) |
HU (1) | HU230316B1 (me) |
IL (2) | IL153834A0 (me) |
JO (1) | JO2372B1 (me) |
MA (1) | MA26929A1 (me) |
ME (1) | ME01311B (me) |
MX (1) | MXPA03000366A (me) |
MY (1) | MY154976A (me) |
NO (1) | NO324700B1 (me) |
NZ (1) | NZ523273A (me) |
PA (1) | PA8522001A1 (me) |
PE (1) | PE20020272A1 (me) |
PL (1) | PL205207B1 (me) |
PT (1) | PT1303490E (me) |
RS (1) | RS50932B (me) |
RU (1) | RU2266284C2 (me) |
SI (1) | SI1303490T1 (me) |
UY (1) | UY26839A1 (me) |
WO (1) | WO2002006236A1 (me) |
ZA (1) | ZA200210207B (me) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1103545E (pt) * | 1999-11-29 | 2004-03-31 | Hoffmann La Roche | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida |
ATE400556T1 (de) * | 2000-07-14 | 2008-07-15 | Hoffmann La Roche | N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
EP1385577B1 (en) * | 2001-04-23 | 2006-04-19 | F. Hoffman-la Roche AG | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
DK1643998T3 (da) * | 2003-07-03 | 2007-12-27 | Hoffmann La Roche | NK1/NK3-antagonister til behandling af skizofreni |
WO2006002860A1 (en) | 2004-07-06 | 2006-01-12 | F. Hoffmann-La Roche Ag | Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
WO2006089674A2 (en) | 2005-02-25 | 2006-08-31 | F.Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
DE602006005624D1 (de) * | 2005-03-23 | 2009-04-23 | Hoffmann La Roche | Metaboliten für nk-i-antagonisten zur emesis |
JP2008280248A (ja) * | 2005-11-02 | 2008-11-20 | Eisai R & D Management Co Ltd | アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8966414B2 (en) | 2009-05-29 | 2015-02-24 | Cypress Semiconductor Corporation | Implementing a circuit using an integrated circuit including parametric analog elements |
US9858367B1 (en) * | 2009-08-31 | 2018-01-02 | Cypress Semiconductor Corporation | Integrated circuit including parametric analog elements |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
EP2727590B1 (en) | 2009-11-18 | 2015-10-21 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
DK2744497T3 (en) | 2011-10-18 | 2016-08-01 | Helsinn Healthcare Sa | THERAPEUTIC COMBINATION OF netupitant AND palonosetron |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
AP2014007805A0 (en) | 2011-12-28 | 2014-07-31 | Cytokinetics Inc The Regents Of The University Of California | Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA034922B1 (ru) | 2013-03-15 | 2020-04-07 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
ES2890077T3 (es) | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
ES2864707T3 (es) | 2013-03-15 | 2021-10-14 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
JP5806420B1 (ja) | 2013-11-08 | 2015-11-10 | キッセイ薬品工業株式会社 | カルボキシメチルピペリジン誘導体 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US10350098B2 (en) * | 2013-12-20 | 2019-07-16 | Volcano Corporation | Devices and methods for controlled endoluminal filter deployment |
BR112015032160B1 (pt) | 2014-02-07 | 2021-11-30 | Global Blood Therapeutics, Inc | Ansolvato cristalino de composto, composição e composição farmacêutica |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
CN106588899B (zh) * | 2015-10-15 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用 |
TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之劑量方案 |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
JP7271437B2 (ja) | 2017-04-10 | 2023-05-11 | チェイス セラピューティクス コーポレイション | Nk1拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法 |
US11266633B2 (en) | 2017-06-30 | 2022-03-08 | Chase Therapeutics Corporation | NK-1 antagonist compositions and methods for use in treating depression |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56106286A (en) | 1980-01-28 | 1981-08-24 | Nippon Musical Instruments Mfg | Electronic musical instrument |
EP0103545A3 (en) | 1982-09-13 | 1984-10-03 | Arc Technologies Systems, Ltd. | Electrode for arc furnaces |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
NZ277839A (en) | 1993-12-29 | 1998-01-26 | Merck Sharp & Dohme | Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
NZ513322A (en) * | 1999-02-24 | 2004-07-30 | F | Phenyl- and pyridinyl derivatives |
DE60014216T2 (de) | 1999-02-24 | 2006-03-02 | F. Hoffmann-La Roche Ag | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
PT1103545E (pt) * | 1999-11-29 | 2004-03-31 | Hoffmann La Roche | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida |
ATE400556T1 (de) * | 2000-07-14 | 2008-07-15 | Hoffmann La Roche | N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2001
- 2001-07-09 AT AT01949475T patent/ATE400556T1/de active
- 2001-07-09 IL IL15383401A patent/IL153834A0/xx unknown
- 2001-07-09 BR BRPI0112475A patent/BRPI0112475B8/pt not_active IP Right Cessation
- 2001-07-09 NZ NZ523273A patent/NZ523273A/en not_active IP Right Cessation
- 2001-07-09 ES ES01949475T patent/ES2309075T3/es not_active Expired - Lifetime
- 2001-07-09 MX MXPA03000366A patent/MXPA03000366A/es active IP Right Grant
- 2001-07-09 CA CA002415890A patent/CA2415890C/en not_active Expired - Lifetime
- 2001-07-09 JP JP2002512140A patent/JP3950044B2/ja not_active Expired - Lifetime
- 2001-07-09 EP EP01949475A patent/EP1303490B1/en not_active Expired - Lifetime
- 2001-07-09 CZ CZ20030428A patent/CZ303639B6/cs not_active IP Right Cessation
- 2001-07-09 DE DE60134749T patent/DE60134749D1/de not_active Expired - Lifetime
- 2001-07-09 WO PCT/EP2001/007850 patent/WO2002006236A1/en active IP Right Grant
- 2001-07-09 RS YUP-6/03A patent/RS50932B/sr unknown
- 2001-07-09 SI SI200130848T patent/SI1303490T1/sl unknown
- 2001-07-09 ME MEP-2008-770A patent/ME01311B/me unknown
- 2001-07-09 HU HU0301311A patent/HU230316B1/hu unknown
- 2001-07-09 AU AU7061901A patent/AU7061901A/xx active Pending
- 2001-07-09 CN CNB018128246A patent/CN1178917C/zh not_active Expired - Lifetime
- 2001-07-09 PL PL365684A patent/PL205207B1/pl unknown
- 2001-07-09 RU RU2003102612/04A patent/RU2266284C2/ru active
- 2001-07-09 PT PT01949475T patent/PT1303490E/pt unknown
- 2001-07-09 KR KR10-2003-7000476A patent/KR100501608B1/ko active IP Right Grant
- 2001-07-09 DK DK01949475T patent/DK1303490T3/da active
- 2001-07-10 JO JO2001106A patent/JO2372B1/en active
- 2001-07-11 EG EG2001070771A patent/EG24968A/xx active
- 2001-07-11 PA PA20018522001A patent/PA8522001A1/es unknown
- 2001-07-12 US US09/904,059 patent/US6593472B2/en not_active Expired - Lifetime
- 2001-07-12 GT GT200100137A patent/GT200100137A/es unknown
- 2001-07-12 MY MYPI20013310A patent/MY154976A/en unknown
- 2001-07-13 AR ARP010103335A patent/AR029717A1/es active IP Right Grant
- 2001-07-13 UY UY26839A patent/UY26839A1/es not_active IP Right Cessation
- 2001-07-13 PE PE2001000704A patent/PE20020272A1/es active IP Right Grant
-
2002
- 2002-12-17 ZA ZA200210207A patent/ZA200210207B/en unknown
-
2003
- 2003-01-02 HR HR20030003A patent/HRP20030003B1/xx not_active IP Right Cessation
- 2003-01-07 IL IL153834A patent/IL153834A/en active IP Right Grant
- 2003-01-07 US US10/337,543 patent/US6747026B2/en not_active Expired - Lifetime
- 2003-01-13 NO NO20030154A patent/NO324700B1/no not_active IP Right Cessation
- 2003-01-13 MA MA26997A patent/MA26929A1/fr unknown
- 2003-01-14 EC EC2003004431A patent/ECSP034431A/es unknown
- 2003-07-09 US US10/616,276 patent/US6897226B2/en not_active Expired - Lifetime
- 2003-08-21 US US10/645,895 patent/US6806370B2/en not_active Expired - Lifetime
-
2004
- 2004-02-12 HK HK04100947A patent/HK1058198A1/xx not_active IP Right Cessation
-
2008
- 2008-10-07 CY CY20081101108T patent/CY1108557T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME01311B (me) | N-oksidi kao proljekovi 4-fenil-piridinskih derivata koji su antagonisti nki receptora | |
YU8703A (sh) | Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1 | |
HRP20050708A2 (en) | Piperidine-benzenesulfonamide derivatives | |
ES2171109A1 (es) | Derivados de 4-fenil-piridina. | |
HRP20020175B1 (en) | N-heterocyclikc derivatives as nos inhibitors | |
BR0111538A (pt) | Derivados de 1,3,8-triaza-espiro 4,5!decan-4-ona como antogonistas de receptor de neurocinina | |
RS51161B (sr) | 5-supstituisani hinolin- ili izohinolin-derivati,postupak za njihovo dobijanje i njihova primena u suzbijanju zapaljenja | |
BRPI0518615A2 (pt) | derivados de malonamida | |
HU191643B (en) | Process for preparing new n-phenyl-n'-cycloalkyl-alkanoyl-piperazine derivatives | |
RU2007125659A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
EA200300071A1 (ru) | Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина | |
BR0011097A (pt) | Derivados de 5-fenil-piridina | |
RS51462B (en) | TRIAZOLOPYRIDINE CARBOXAMID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | |
BR0110592A (pt) | Composto, método para a preparação do composto, composições farmacêuticas, métodos de preparação de uma composição farmacêutica, de tratamento de distúrbios do cns, da ansiedade e/ou depressão, da doença de parkinson e de vìcio | |
MXPA04003935A (es) | Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato. | |
CA2366205A1 (en) | Biphenyl derivatives | |
MX2012008147A (es) | Derivados de pirrazolopiridina. | |
BRPI0418375A (pt) | derivados de diaza-espiropiperidina | |
BRPI0514077A (pt) | derivados de benzilóxi como inibidores de maob | |
PL378343A1 (pl) | Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny | |
HRP20161024T1 (hr) | Novi derivati amino-pirolina i njihova uporaba u sprječavanju i/ili liječenju metaboličkog sindroma | |
BR0212839A (pt) | Derivados de alquilaminopiridazinona substituìdos, processo para a preparação destes e composição farmacêutica contendo os mesmos | |
BR0103180A (pt) | Derivados do diazabiciclooctano e suas utilizações terapêuticas | |
BR0113348A (pt) | Pró-drogas para ligantes de receptores de nmda | |
HRP20070518T5 (en) | DERIVATIVES OF 4-OXO-4,6,7,8-TETRAHYDROPYRROLO-1,2-a PYRAZINE-6-CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF |